Ophthalmologist Sonal Tuli, MD, discusses the FDA’s recent approval of teprotumumab for thyroid eye disease and what this new drug adds to the treatment landscape for this condition.
Eric A. Dietrich, PharmD, BCPS, and Kyle Davis, PharmD, BCPS
Eric A. Dietrich, PharmD, BCPS, and Kyle Davis, PharmD, BCPS
Subclinical hypothyroidism is an elevation in thyroid-stimulating hormone concentrations, with free thyroxine and free triiodothyronine concentrations within the reference range, with or without signs or...
